The Clinical Efficacy and Safety of the Sahastara Remedy versus Diclofenac in the Treatment of Osteoarthritis of the Knee: A Double-Blind, Randomized, and Controlled Trial
Table 7
Blood pressure, renal functions, and liver functions in safety issue.
Data
Follow-up
Treatment
value
SHT
Diclofenac
Blood pressure
Systolic blood pressure (normal ≤ 140 mm.Hg.)
Day 0
123.55 (11.42)
121.83 (13.03)
0.66
Day 14
126.77 (10.13)
127.00 (14.42)†
Day 28
123.54 (12.79)
128.67 (17.95)
Diastolic blood pressure (normal ≤ 90 mm.Hg.)
Day 0
82.90 (8.24)
80.50 (8.13)
0.68
Day 14
84.03 (6.38)
83.50 (7.08)
Day 28
83.55 (7.09)
84.67 (6.81)†
Renal functions
Blood urea nitrogen; BUN (mg/dL) (ref. range = 7.0–18.0)
Day 0
13.74 (4.69)
15.35 (4.55)
0.15
Day 14
13.98 (3.87)
14.70 (4.67)
Day 28
13.54 (3.89)
14.96 (3.52)
Creatinine (mg/dL) (ref. range = 0.7–1.3)
Day 0
0.84 (0.27)
0.80 (0.20)
0.60
Day 14
0.82 (0.22)
0.79 (0.23)
Day 28
0.81 (0.24)
0.80 (0.20)
Liver functions
AST (U/L) (ref. range = 15–37)
Day 0
28.00 (19.50)
22.33 (10.35)
0.45
Day 14
25.77 (12.54)
30.50 (20.88)
Day 28
21.61 (7.05) †
29.00 (14.93) †
ALT (U/L) (ref. range = 30–65)
Day 0
46.48 (23.94)
40.90 (12.92)
0.00
Day 14
44.13 (23.95)
55.70 (36.66)†††
Day 28
41.03 (11.45)
56.37 (32.33)†††
ALP (U/L) (ref. range = 50–136)
Day 0
108.26 (25.95)
98.27 (23.26)
0.19
Day 14
110.13 (46.30)
98.23 (21.85)
Day 28
113.84 (35.68)
106.17 (30.68)††
Statistical analysis: repeated measured ANOVA, Friedman’s test. Significant difference from day 0 within group (), significant difference from day 0 within group (), and significant difference from day 0 within group ().
